As of April 16, 2025, CytomX Therapeutics (CTMX) has a market cap of $50.583 million USD. According to our data, CytomX Therapeutics is ranked No.8059 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 16, 2025 | $50.58 M |
-37.25%
|
Dec 31, 2024 | $80.61 M |
-33.55%
|
Dec 29, 2023 | $0.12 B |
-3.13%
|
Dec 30, 2022 | $0.13 B |
-63.05%
|
Dec 31, 2021 | $0.34 B |
-33.89%
|
Dec 31, 2020 | $0.51 B |
-21.18%
|
Dec 31, 2019 | $0.65 B |
-44.97%
|
Dec 31, 2018 | $1.18 B |
-28.47%
|
Dec 29, 2017 | $1.65 B |
92.08%
|
Dec 30, 2016 | $0.86 B |
-47.34%
|
Dec 31, 2015 | $1.63 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() MacroGenics
MGNX
|
$79.49 M |
-0.000 M
|
![]() USA
|
![]() Mersana Therapeutics
MRSN
|
$43.43 M |
-0.000 M
|
![]() USA
|
![]() Zymeworks
ZYME
|
$0.76 B |
-0.000 M
|
![]() Canada
|
![]() Adicet Bio
ACET
|
$48.92 M |
0.000 M
|
![]() USA
|
![]() Nektar Therapeutics
NKTR
|
$0.12 B |
0.000 M
|
![]() USA
|
![]() Xencor
XNCR
|
$0.67 B |
0.000 M
|
![]() USA
|
![]() Iovance Biotherapeutics
IOVA
|
$1.06 B |
-0.000 M
|
![]() USA
|
![]() Adaptimmune Therapeutics
ADAP
|
$64.18 M |
-0.000 M
|
![]() UK
|
![]() Allogene Therapeutics
ALLO
|
$0.32 B |
0.000 M
|
![]() USA
|
![]() BioAtla
BCAB
|
$18.58 M |
0.000 M
|
![]() USA
|
![]() Arcus Biosciences
RCUS
|
$0.85 B |
-0.000 M
|
![]() USA
|
![]() Blueprint Medicines
BPMC
|
$5.21 B |
0.000 M
|
![]() USA
|
Market Cap | = | CTMX Stock Price | * | CTMX Shares Outstanding |
= | $0.63 | * | 80.10 M | |
= | $50.58 M |